Clinical Pharmacoepidemiology Training Grant

临床药物流行病学培训补助金

基本信息

  • 批准号:
    10404484
  • 负责人:
  • 金额:
    $ 61.08万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-07-01 至 2026-06-30
  • 项目状态:
    未结题

项目摘要

Project Summary The Department of Biostatistics, Epidemiology, and Informatics (DBEI), the Center for Clinical Epidemiology and Biostatistics (CCEB) and the Center for Pharmacoepidemiology Research and Training (CPeRT) of the University of Pennsylvania (Penn) Perelman School of Medicine submit this renewal application to continue and improve our innovative and highly successful post-doctoral training program in clinical pharmaco- epidemiology. Pharmacoepidemiology is the study of the use and effects of medications and other medical products in populations. Our training program attracts highly qualified clinicians from across the nation. This two- to three-year intensive clinical research training program is designed to: 1) train clinicians to be rigorous and independent investigators able to formulate research questions and use a wide range of pharmacoepidemiologic approaches to answer those questions; 2) provide an understanding of the basic principles of clinical pharmacology; 3) provide intensive, supervised research experience with mentors in clinical pharmacoepidemiology and other content-area mentors; and 4) strengthen the links between clinical epidemiology and clinical pharmacology. To learn the basic sciences of clinical research, fellows matriculate in our highly-successful Master of Science in Clinical Epidemiology (MSCE) or PhD in Epidemiology degree programs and complete required courses in clinical epidemiology, pharmacoepidemiology, outcomes measurement, biostatistics, and database management; elective courses in drug development, pharmacology and other areas relevant to the fellows' interests and experience; independent readings; and participation in research seminars and other activities within DBEI/CCEB and CPeRT. These skills are applied to the primary focus of the training program, which is the design, implementation, analysis, and publication of mentored independent research projects of the fellow's design that targets their independent research career goals. Strengths of the program include: 1) the large pool of highly qualified candidates with clinical training seeking rigorous research training in pharmacoepidemiology; 2) the long history of successful research training programs in the DBEI/CCEB, including in pharmacoepidemiology and comparative effectiveness research/patient-centered outcomes research; 3) the comprehensive course offerings and research programs available to fellows; and 4) the successful training record of the program director and other faculty. In addition, the availability of the CPeRT and other CCEB faculty, who provide expertise in a wide range of methodologic and clinical disciplines; numerous epidemiologic databases useful for research projects and training; a broad array of specialized analytic capabilities available for clinical studies (e.g., clinical trials, case-control, cohort, self-controlled designs); and the faculty members' commitment to collaborative research and training, combine to provide an ideal environment for this program.
项目概要 生物统计、流行病学和信息学系 (DBEI)、临床流行病学中心 和生物统计学(CCEB)以及药物流行病学研究和培训中心(CPeRT) 宾夕法尼亚大学 (Penn) 佩雷尔曼医学院提交此续签申请以继续 并改进我们在临床药物方面创新且非常成功的博士后培训计划 流行病学。药物流行病学是对药物和其他医学用途和效果的研究 产品在人群中的应用。我们的培训计划吸引了来自全国各地的高素质临床医生。 这个为期两到三年的强化临床研究培训计划旨在:1)培训临床医生 是严谨和独立的研究人员,能够提出研究问题并使用广泛的 回答这些问题的药物流行病学方法; 2)提供对基本知识的理解 临床药理学原理; 3)在导师的指导下提供密集的、有监督的研究经验 临床药物流行病学和其他内容领域导师; 4)加强临床之间的联系 流行病学和临床药理学。为了学习临床研究的基础科学,研究员入读 我们非常成功的临床流行病学理学硕士 (MSCE) 或流行病学博士学位 计划并完成临床流行病学、药物流行病学、结果方面的必修课程 测量、生物统计学和数据库管理;药物开发、药理学选修课 以及与研究员的兴趣和经验相关的其他领域;独立阅读;和参与 DBEI/CCEB 和 CPeRT 内的研究研讨会和其他活动。这些技能适用于初级 培训计划的重点是指导的设计、实施、分析和发布 研究员针对其独立研究职业目标而设计的独立研究项目。 该计划的优势包括:1)拥有大量接受过临床培训的高素质候选人 寻求严格的药物流行病学研究培训; 2)成功研究培训的悠久历史 DBEI/CCEB 项目,包括药物流行病学和比较有效性 研究/以患者为中心的结果研究; 3)全面的课程设置和研究项目 可供研究员使用; 4) 项目主任和其他教员的成功培训记录。此外, CPeRT 和其他 CCEB 教员的可用性,他们提供广泛的方法学方面的专业知识 和临床学科;许多对研究项目和培训有用的流行病学数据库;广泛的 一系列可用于临床研究的专业分析功能(例如临床试验、病例对照、队列、 自控设计);以及教职员工对合作研究和培训的承诺,将 为该计划提供理想的环境。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sean Hennessy其他文献

Sean Hennessy的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sean Hennessy', 18)}}的其他基金

Drug Interactions Involving Second-generation Antipsychotic Agents Leading to Sudden Cardiac Arrest
涉及第二代抗精神病药物的药物相互作用导致心脏骤停
  • 批准号:
    10661090
  • 财政年份:
    2022
  • 资助金额:
    $ 61.08万
  • 项目类别:
Drug Interactions Involving Second-generation Antipsychotic Agents Leading to Sudden Cardiac Arrest
涉及第二代抗精神病药物的药物相互作用导致心脏骤停
  • 批准号:
    10501196
  • 财政年份:
    2022
  • 资助金额:
    $ 61.08万
  • 项目类别:
Stimulant Overdose in the Medicaid Population: Who is at Risk, and When are They at Risk
医疗补助人群中兴奋剂过量:谁有风险,何时有风险
  • 批准号:
    10662407
  • 财政年份:
    2021
  • 资助金额:
    $ 61.08万
  • 项目类别:
Stimulant Overdose in the Medicaid Population: Who is at Risk, and When are They at Risk
医疗补助人群中兴奋剂过量:谁有风险,何时有风险
  • 批准号:
    10392130
  • 财政年份:
    2021
  • 资助金额:
    $ 61.08万
  • 项目类别:
Drug-Drug Interactions Involving Methadone and Buprenorphine
涉及美沙酮和丁丙诺啡的药物相互作用
  • 批准号:
    10436942
  • 财政年份:
    2019
  • 资助金额:
    $ 61.08万
  • 项目类别:
Enhancing the Utility of the Trend-in-Trend Research Design
增强趋势研究设计的实用性
  • 批准号:
    10017817
  • 财政年份:
    2019
  • 资助金额:
    $ 61.08万
  • 项目类别:
Drug-Drug Interactions Involving Methadone and Buprenorphine
涉及美沙酮和丁丙诺啡的药物相互作用
  • 批准号:
    10205012
  • 财政年份:
    2019
  • 资助金额:
    $ 61.08万
  • 项目类别:
Drug-Drug Interactions Involving Methadone and Buprenorphine
涉及美沙酮和丁丙诺啡的药物相互作用
  • 批准号:
    10649570
  • 财政年份:
    2019
  • 资助金额:
    $ 61.08万
  • 项目类别:
Enhancing the Utility of the Trend-in-Trend Research Design
增强趋势研究设计的实用性
  • 批准号:
    9813026
  • 财政年份:
    2019
  • 资助金额:
    $ 61.08万
  • 项目类别:
Enhancing the Utility of the Trend-in-Trend Research Design
增强趋势研究设计的实用性
  • 批准号:
    10162467
  • 财政年份:
    2019
  • 资助金额:
    $ 61.08万
  • 项目类别:

相似国自然基金

权力何以授予:目标理论视角下领导授权行为的形成机制研究
  • 批准号:
    71702005
  • 批准年份:
    2017
  • 资助金额:
    18.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Leveraging genetic and electronic health records data to identify novel targets and drugs for treating alcohol
利用遗传和电子健康记录数据来确定治疗酒精的新靶点和药物
  • 批准号:
    10888495
  • 财政年份:
    2023
  • 资助金额:
    $ 61.08万
  • 项目类别:
Addressing Barriers to the Comprehensive Use of Statins in HIV: The ABACUS-HIV Study
消除他汀类药物综合使用治疗艾滋病毒的障碍:ABACUS-HIV 研究
  • 批准号:
    10762138
  • 财政年份:
    2023
  • 资助金额:
    $ 61.08万
  • 项目类别:
Mid-Career Mentoring Award For Patient-Oriented Research in Frailty and Health Outcomes
职业生涯中期指导奖,表彰以患者为导向的虚弱和健康结果研究
  • 批准号:
    10448534
  • 财政年份:
    2022
  • 资助金额:
    $ 61.08万
  • 项目类别:
TreeScan to Evaluate the Safety of New Drugs in Pediatric Populations
TreeScan 评估新药在儿科人群中的安全性
  • 批准号:
    10539032
  • 财政年份:
    2022
  • 资助金额:
    $ 61.08万
  • 项目类别:
Sudden Death Associated with Substance Use
与药物使用相关的猝死
  • 批准号:
    10508030
  • 财政年份:
    2022
  • 资助金额:
    $ 61.08万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了